Advertisement

Topics

AstraZeneca to Divest U.S. Synagis Rights to Sobi

11:37 EST 13 Nov 2018 | Pharmaceutical Processing

AstraZeneca sells U.S. rights to RSV therapy Synagis to Sobi for $1.5 billion upfront.
Contributed Author: 
AstraZeneca

Original Article: AstraZeneca to Divest U.S. Synagis Rights to Sobi

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca to Divest U.S. Synagis Rights to Sobi"

Advertisement
Quick Search
Advertisement
Advertisement